OBJECTIVES: Bevacizumab in combination with platinum-based chemotherapy improves progression free survival (PFS) over chemotherapy alone in advanced or metastatic NSCLC. The aim of this analysis was to assess potential cost savings for society derived from the clinical benefits of bevacizumab-based therapy in metastatic NSCLC patients returning to work in France. METHODS: Indirect cost calculation was performed using human capital approach in the population of progression free metastatic NSCLC patients. Clinical outcomes in terms of PFS from the two bevacizumab phase III trials (Reck et al, 2009, Sandler et al, 2006) were applied to the incidence cases of non-squamous metastatic NSCLC patients in France, taking into account only age groups eligible to work. Clinical experts were consulted to estimate the percentage of PFS patients who return to work after the induction phase. It was estimated that 20% of PFS patients, below 55 years of age and with performance status 0-1 would maintain their prior employment status (60% part-time, 40% full-time). Cost savings were analyzed for 1 year and 1.5 year time horizons applying French labor costs.  RESULTS: Indirect cost savings per patient returning to work were €21,667 at year 1 and €39,001 at year 1.5. A change in employment pattern (40% part-time, 60% full-time) led to an approximate 14% increase of savings for both time horizons (€24,763 at year 1 and €44,573 at year 1.5). A 10% alteration of labor cost in either direction resulted in cost savings that were 10% higher/lower.   CONCLUSIONS: Bevacizumab-based therapy could result in considerable cost savings in progression free NSCLC patients. This societal economic benefit adds to the patients’ clinical benefit of increased survival outcomes.